Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TGFBR2 KO Anti-CD70 CAR-NK cells |
| Synonyms | |
| Therapy Description |
TGFBR2 KO Anti-CD70 CAR-NK cells are allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD70 with TGFBR2 deletion, which potentially induces cytotoxicity in CD70-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TGFBR2 KO Anti-CD70 CAR-NK cells | Allogeneic TGFBR-2 KO anti-CD70 CAR NK cells | CD70 Immune Cell Therapy 11 | TGFBR2 KO Anti-CD70 CAR-NK cells are allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD70 with TGFBR2 deletion, which potentially induces cytotoxicity in CD70-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07072234 | Phase I | Cyclophosphamide + Fludarabine TGFBR2 KO Anti-CD70 CAR-NK cells Dexamethasone | Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |